Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients



Status:Completed
Conditions:Lung Cancer, Lung Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/22/2018
Start Date:July 2014
End Date:June 2016

Use our guide to learn which trials are right for you!

Assess the safety and feasibility of local oncological drug delivery into the bronchial wall
after recanalization of subjects with malignant airway obstruction. Safety and feasibility
(technical success) will be assessed.

This localized delivery is intended as an adjunct therapy and all subjects will receive
standard of care oncology therapy as determined by their treating physicians.


Inclusion Criteria:

- Life expectancy of at least 12 weeks

- Adequate bone marrow, liver, and renal function

- Scheduled to undergo bronchoscopy for malignant airway obstruction as standard medical
care

- Pathologically confirmed, unresectable primary or recurrent non-small cell lung cancer

- Measurable disease with obstruction into the airway

- Pathologically confirmed, unresectable primary or recurrent non-small cell lung cancer

- Patients undergo recanalization procedure of tumor during bronchoscopy

- Investigator is able to insert and deploy the Blowfish Catheter into the airway after
recanalization

Exclusion Criteria:

- Second primary malignancy, except for non-melanoma skin cancer and in situ cervical
cancer

- Pregnant or nursing female subjects, or female subjects of child bearing potential who
refuse to take a pregnancy test prior to their enrollment in this study

- Uncontrolled infection

- Presence or recent history of any systemic disorder or conditions, such as:

- uncontrolled hypertension

- type 1 diabetes

- severe pulmonary hypertension

- acute kidney injury

- stroke (within the last 6 month)

- myocardial infarction (within the last 3 months)

- Individuals with neurological, mental or psychiatric disorders

- Concurrent participation in another study involving investigational drugs or
investigational medical devices

- Other (non-cancer) disease not stabilized within 1 month before the Screening Visit

- Known hypersensitivity to paclitaxel, Cremophor EL, or iodinated contrast media

- Any serious, uncontrolled comorbidity or condition that an Investigator believes would
interfere with the intent of the study or would make participation not in the best
interest of the patient Intraoperative Exclusion Criteria

- Use of pulmonary airway stents and/or ongoing or initiation of local external beam or
brachytherapy radiation

- Any intraoperative complications that per the investigator's judgment increase the
risk to the patient.
We found this trial at
3
sites
3400 N Charles St
Baltimore, Maryland 21205
410-516-8000
Principal Investigator: Lonny Yarmus, DO
Phone: 410-502-2533
Johns Hopkins University The Johns Hopkins University opened in 1876, with the inauguration of its...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
(919) 962-2211
Principal Investigator: Jason Akulien, MD
University of North Carolina at Chapel Hill Carolina’s vibrant people and programs attest to the...
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Raleigh, North Carolina
Principal Investigator: Momen Wahidi, MD
?
mi
from
Raleigh, NC
Click here to add this to my saved trials